Copenhagen Heart Failure With Preserved Ejection Fraction
Recruiting · NCT06685237 · Observational (researchers observe without assigning treatment) · Lead sponsor: Tor Biering-Sørensen
View the official record on ClinicalTrials.gov →What this trial is about
Heart failure with preserved ejection fraction (HFpEF) has grown to become the dominant form of heart failure (HF) worldwide, in tandem with ageing of the general population and the increasing prevalence of obesity, diabetes mellitus and hypertension. In 2020, \> 70% of patients with heart failure had preserved ejection fraction. The incidence and prevalence of HFpEF has been growing by 10% every 10 years relative to HF with reduced ejection fraction (HFrEF). In 2017, the prevalence of HFpEF varied from 1% to 14% based on available data from Europe and USA. HFpEF is associated with high morbidity and mortality, and patients with HFpEF have similarly high hospitalization rates as patients with HFrEF. Hence, HFpEF poses a substantial global health challenge. Despite its prevalence, HFpEF remains undiagnosed and underrecognized, necessitating a comprehensive approach to both identification and management. Ensuring successful treatment necessitates early identification of HFpEF. Consequently, a targeted screening strategy has been devised for the identification of HFpEF patients. Given the higher prevalence of heart failure (HF) in the elderly population, testing the screening strategy is imperative to customize it to the specific needs of vulnerable patients who may be more inclined to decline participation in the screening program.
Who can take part
Inclusion criteria
- Residence in the Capital Region of Denmark
- Age ≥ 50 years
- At least two risk factors for HFpEF defined as any of the following (for age ≥ 60 years, only one):
- Hypertension
- Diabetes mellitus
- Chronic kidney disease
- Atrial fibrillation
- BMI \> 25 kg/m2
- Previous heart valve surgery
- Ischemic heart disease
- Obstructive sleep apnea
- Furosemide 40 mg
Exclusion criteria
- Age ≥ 90 years
- Prevalent HF
- Dementia
- Nursing home
- Amyloidosis
- Hemodialysis
- Cancer diagnosed within the past 5 years (skin cancer not included)
- Prior solid organ transplantation
- Lung disease defined as any of the following:
- World Health Organization Group 1 pulmonary hypertension
- Chronic pulmonary embolism
- Lung fibrosis
- Chronic obstructive pulmonary disease (COPD)
- Home oxygen
Where it is running
1 location listed.
- Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte Hospital - Hellerup, Denmark